FBIO
$3.12
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
Intraday
Recent News
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M
Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205M upon the closing of the transaction. In December 2023, Sentynl Therapeutics assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration on Ja
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability
We feel now is a pretty good time to analyse Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) business as it appears the...
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of +125.58% and -25.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech: Q3 Earnings Snapshot
BAY HARBOR ISLAND, Fla. AP) — Fortress Biotech Inc. FBIO) on Friday reported earnings of $5.9 million in its third quarter.
Kamada (KMDA) Misses Q3 Earnings Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -10.00% and +1.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?